OncoMatch/Clinical Trials/NCT04634552
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Is NCT04634552 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Talquetamab for hematological malignancies.
Treatment: Talquetamab — The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: CAR-T cell therapy or T cell redirection therapy
Exception: Cohort B, Cohort D and Cohort E: T cell redirection therapy within 3 months
Cohort A and Cohort C only: exposed to a CAR-T or T cell redirection therapy at any time. Cohort B, Cohort D and Cohort E: T cell redirection therapy within 3 months
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama Birmingham · Birmingham, Alabama
- University of Arkansas for Medical Sciences · Little Rock, Arkansas
- City of Hope · Duarte, California
- Memorial Healthcare System · Hollywood, Florida
- Emory University Winship Cancer Institute · Atlanta, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04634552 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy or T cell redirection therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify